Skip to main content

Advertisement

SpringerLink
Log in

Overview on the role of preoperative therapy in the management of kidney cancer

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The advent of molecular therapy through targeted kinase inhibitors (TKI) has revolutionized the management of renal cell carcinoma. Although surgical resection remains the cornerstone of any therapeutic plan, an increased risk of morbidity and mortality can be of concern in large and complex bulky tumors. Preoperative therapy with TKIs is hypothesized to facilitate resectability, reduce surgical morbidity and allow nephron-sparing surgery. Many concerns on the safety, efficacy and tolerability of these agents before surgery have halted the progress in this setting. In this paper, we will review the indications and safety of preoperative TKIs in RCC as well as the future approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    PubMed  Google Scholar 

  3. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–54.

    CAS  PubMed  Google Scholar 

  4. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008–166.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. S Damodaran, EJ Abel (2019) Pre-surgical treatment of Renal cell carcinoma. In: Diagnosis and surgical management of renal tumors. Springer, New York, pp 247–262

    Google Scholar 

  6. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016;8(2):130–41.

    CAS  PubMed  Google Scholar 

  7. Van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14(8):2431–6.

    PubMed  Google Scholar 

  8. Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181(2):518–23.

    CAS  PubMed  Google Scholar 

  9. Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27(4):533–9.

    CAS  PubMed  Google Scholar 

  10. Rini BI, Garcia J, Elson P, Wood L, Shah S, Stephenson A, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187(5):1548–54.

    CAS  PubMed  Google Scholar 

  11. Jonasch E, Wood CG, Matin SF, Tu S-M, Pagliaro LC, Corn PG, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology. 2010;75(5):1108–13.

    PubMed  Google Scholar 

  14. Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106(9):1270–6.

    PubMed  Google Scholar 

  15. Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22(5):1041–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang Y, Li Y, Deng J, Ji Z, Yu H, Li H. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma. PLoS ONE. 2015;10(2):e0115896.

    PubMed  PubMed Central  Google Scholar 

  17. Hatiboglu G, Hohenfellner M, Arslan A, Hadaschik B, Teber D, Radtke JP, et al. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbeck’s Arch Surg. 2017;402(4):637–44.

    Google Scholar 

  18. Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, et al. Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncol. 2016;2(10):1303–9.

    PubMed  Google Scholar 

  19. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.

    PubMed  Google Scholar 

  20. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001;166(1):6–18.

    CAS  PubMed  Google Scholar 

  21. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014;66(5):874–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol. 2015;194(2):297–303.

    CAS  PubMed  Google Scholar 

  23. Lane BR, Derweesh IH, Kim HL, Klink J, Ercole CE, Palazzi KL, et al (2015) Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. In: Urologic oncology: seminars and original investigations. Elsevier, Amsterdam, pp 112–e15.

    Google Scholar 

  24. Voylenko O, Stakhovskyi O, Kononenko O, Pikul M, Vitruk Y, Stakhovsky E. Neoadjuvant targeted therapy in patients with localized renal-cell carcinoma. Eur Urol Suppl. 2018;17(2):e956.

    Google Scholar 

  25. Lebacle C, Bensalah K, Bernhard J-C, Albiges L, Laguerre B, Gross-Goupil M, et al. Evaluation of axitinib to downstage cT 2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int. 2018;123:804–10.

    PubMed  Google Scholar 

  26. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007;178(4):1189–95.

    PubMed  Google Scholar 

  27. Marshall FF, Dietrick DD, Baumgartner WA, Reitz BA. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol. 1988;139(6):1166–71.

    CAS  PubMed  Google Scholar 

  28. Peters I, Winkler M, Jüttner B, Teebken OE, Herrmann TR, von Klot C, et al. Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report. World J Urol. 2014;32(1):245–8.

    CAS  PubMed  Google Scholar 

  29. Sassa N, Kato M, Funahashi Y, Maeda M, Inoue S, Gotoh M. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma. Jpn J Clin Oncol. 2014;44(4):370–3.

    PubMed  Google Scholar 

  30. Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, et al. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011;107(5):724–8.

    PubMed  Google Scholar 

  31. Horn T, Thalgott MK, Maurer T, Hauner K, Schulz S, Fingerle A, et al. Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res. 2012;32(5):1729–35.

    CAS  PubMed  Google Scholar 

  32. Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59(6):912–8.

    CAS  PubMed  Google Scholar 

  33. Bigot P, Fardoun T, Bernhard JC, Xylinas E, Berger J, Rouprêt M, et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol. 2014;32(1):109–14.

    CAS  PubMed  Google Scholar 

  34. Kwon T, Lee J-L, Kim JK, You D, Jeong IG, Song C, et al. The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy. J Cancer Res Clin Oncol. 2014;140(10):1751–8.

    CAS  PubMed  Google Scholar 

  35. Terakawa T, Hussein AA, Bando Y, Guru KA, Furukawa J, Shigemura K, et al. Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study. Anticancer Drugs. 2018;29(6):565–71.

    CAS  PubMed  Google Scholar 

  36. Tanaka Y, Hatakeyama S, Hosogoe S, Tanaka T, Hamano I, Kusaka A, et al. Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava. Int J Clin Oncol. 2018;23(1):134–41.

    CAS  PubMed  Google Scholar 

  37. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35(35):3916–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol. 2011;60(3):448–54.

    CAS  PubMed  Google Scholar 

  39. Patel N, Woo J, Liss MA, Palazzi KL, Randall JM, Mehrazin R, et al. Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches. Can J Urol. 2016;23:8227–333.

    PubMed  Google Scholar 

  40. Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI (2013) Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). In: Urologic oncology: seminars and original investigations. Elsevier, Amsterdam, pp 379–385

    CAS  PubMed  Google Scholar 

  41. Chapin BF, Delacroix SE Jr, Culp SH, Gonzalez GMN, Tannir NM, Jonasch E, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011;60(5):964–71.

    PubMed  PubMed Central  Google Scholar 

  42. Bhindi B, Habermann EB, Mason RJ, Costello BA, Pagliaro LC, Thompson RH, et al. Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma. J Urol. 2018;200:528–534.

    PubMed  Google Scholar 

  43. García-Perdomo HA, Zapata-Copete JA, Castillo-Cobaleda DF. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis. Investig Clin Urol. 2018;59(1):2–9.

    PubMed  Google Scholar 

  44. Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417–427.

    PubMed  Google Scholar 

  45. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2018;5:164–70.

    PubMed Central  Google Scholar 

  46. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    PubMed  PubMed Central  Google Scholar 

  47. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Ikarashi D, Kato Y, Katagiri H, Takahara T, Uesugi N, Shiomi E, et al. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma. Int J Urol. 2018;25(6):630–2.

    PubMed  Google Scholar 

  52. Ikarashi D, Nakamura Y, Shimodate H, Usui Y, Ujiie T, Obara W. Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: a case report. Urol Case Rep. 2019. https://doi.org/10.1016/j.eucr.2019.100839.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi M-C, Levionnois E, et al. Sunitinib prior to planned nephrectomy in metastatic renal cell carcinoma: angiogenesis biomarkers predict clinical outcome in the prospective Phase II PREINSUT trial. Clin Cancer Res. 2018;24(22):5534–42.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

    T. Assi, E. El Rassy, F. Farhat & J. Kattan

Authors
  1. T. Assi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. El Rassy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Farhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Kattan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Assi.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

An approval of the institutional ethics board at Gustave Roussy was obtained.

Informed consent

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Assi, T., El Rassy, E., Farhat, F. et al. Overview on the role of preoperative therapy in the management of kidney cancer. Clin Transl Oncol 22, 11–20 (2020). https://doi.org/10.1007/s12094-019-02136-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02136-5

Keywords

Search

Navigation